The effects of different administration methods of azasetron on preventing nausea and vomiting after gynecological laparoscopic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076786

Enrollment

Unknown

Registered

2023-10-18

Start date

2023-10-20

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

Group A:10mg of azasetron was administered intravenously before induction.

Group B:5mg of azasetron administered intravenously before induction, another 5mg before the end of surgery.

Group C:10mg of azasetron was administered intravenously before the end of surgery.

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years; 2. ASA grade I-III; 3. Weighing <= 60 kg.

Exclusion criteria

Exclusion criteria: 1. Patients with allergy to serotonin antagonists; 2. Impaired hepatic or renal function; 3. History of motion sickness/PONV; 4. Smoking habit.

Design outcomes

Primary

Measure	Time frame
Incidence of nausea and vomiting;Nausea and vomiting frequency;Severity of nausea and vomiting;	—

Secondary

Measure	Time frame
Emergency postoperative antiemesis;	—

Countries

China

Contacts

Public ContactLiping Han

Dalian Municipal Central Hospital

han651310@163.com+86 199 6931 0956

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026